Company TriSalus Life Sciences, Inc.

Equities

TLSI

US89680M1018

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
9.39 ^USD	-7.49%		-8.30%	+11.12%

May. 15	TriSalus Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 15	Earnings Flash (TLSI) TRISALUS LIFE SCIENCES Posts Q1 Revenue $6.5M, vs. Street Est of $5.9M	MT

TriSalus Life Sciences, Inc. is an oncology focused medical technology business providing drug delivery technology with the goal of improving therapeutics delivery to liver and pancreatic tumors. The Companyâs platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. Its two Food and Drug Administration (FDA) cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. Additionally, the Company is exploring the integration of its technology with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of liver and pancreatic indications.

Number of employees: 112

USD in Million	2022	Weight	2023	Weight	Delta
Innovative Drug Delivery Technology and Immune-oncology Therapeutics 100.0 %	-	-	19	100.0 %	-

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	0	nan %	19	100.0 %	-

Managers	Title	Age	Since
Mary Szela CEO	Chief Executive Officer	60	17-12-31
Sean Murphy DFI	Director of Finance/CFO	71	23-08-09
Steven Katz CTO	Chief Tech/Sci/R&D Officer	49	23-08-09
Bryan Cox CTO	Chief Tech/Sci/R&D Officer	62	23-08-09
Jennifer Stevens LAW	General Counsel	63	23-08-09
Richard Marshak PRN	Corporate Officer/Principal	65	23-08-09
Jodi Devlin PRN	Corporate Officer/Principal	-	23-09-04
James Alecxih PRN	Corporate Officer/Principal	59	23-08-09

Members of the board	Title	Age	Since
Kerry Hicks BRD	Director/Board Member	64	23-08-09
Mats Wahlström CHM	Chairman	70	23-08-09
George Martin BRD	Director/Board Member	65	23-08-09
David Matlin BRD	Director/Board Member	62	23-08-09
Sean Murphy DFI	Director of Finance/CFO	71	23-08-09
Mary Szela CEO	Chief Executive Officer	60	17-12-31
Andrew von Eschenbach BRD	Director/Board Member	82	23-08-09
Arjun Desai BRD	Director/Board Member	42	23-08-09
Anil Singhal BRD	Director/Board Member	72	23-08-09

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	27,159,327	12,202,622 ( 44.93 %)	0	44.93 %

Name	Equities	%	Valuation
MedTech Acquisition Sponsor LLC 23.36 %	6,249,999	23.36 %	62 M $
Paul Frankenius 23.05 %	6,167,776	23.05 %	61 M $
Simone Song 5.780 %	1,546,569	5.780 %	15 M $
Gene R. McGrevin 5.196 %	1,390,474	5.196 %	14 M $
Hw Investment Partners LLC 5.120 %	1,370,028	5.120 %	14 M $
Leonard Capital LLC 4.687 %	1,254,259	4.687 %	12 M $
MatlinPatterson Global Advisers LLC 3.483 %	931,904	3.483 %	9 M $
David Matlin 3.483 %	931,903	3.483 %	9 M $
Kerry Hicks 3.129 %	837,326	3.129 %	8 M $
BTO Monarch Luxembourg Holdings SARL 2.878 %	770,013	2.878 %	8 M $

Name	Equities	%	Valuation
BTO Monarch Luxembourg Holdings SARL 14.65 %	588,000	14.65 %	6 M $
Paul Frankenius 5.989 %	240,478	5.989 %	2 M $
Michael Stansky 2.491 %	100,000	2.491 %	993 000 $
David Matlin 2.491 %	100,000	2.491 %	993 000 $
Christopher Dewey 1.681 %	67,500	1.681 %	670 275 $
Leonard Capital LLC 1.302 %	52,278	1.302 %	519 121 $
Mats Wahlström 1.245 %	50,000	1.245 %	496 500 $

Name	Equities	%	Valuation
Magnetar Financial LLC -	767,163	-	912 924 $
Highbridge Capital Management LLC -	662,068	-	787 861 $
Deerfield Management Co. LP (Private Equity) -	333,333	-	396 666 $
Polar Asset Management Partners, Inc. -	285,864	-	340 178 $
Exos Asset Management LLC -	167,610	-	199 456 $
Vestcor, Inc. -	148,755	-	177 018 $
MSD Partners LP -	133,333	-	158 666 $
Wolverine Asset Management LLC -	117,290	-	139 575 $
Bracebridge Capital LLC -	92,880	-	110 527 $
Walleye Capital LLC -	80,883	-	96 251 $

TriSalus Life Sciences, Inc.

6272 West 91st Avenue

80031, Westminster

http://www.trisaluslifesci.com

address TriSalus Life Sciences, Inc.(TLSI)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.85 USD

Average target price

16 USD

Spread / Average Target

+62.44%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
TRISALUS LIFE SCIENCES, INC.	+11.12%	264M
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	106B
ARGENX SE	-2.59%	21.96B
BIONTECH SE	-12.38%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-3.35%	18.08B
WUXI APPTEC CO., LTD.	-38.57%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.32B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.42B

Bio Therapeutic Drugs